1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses

In the prespecified final analysis of overall survival (OS) in the NETTER-1 study, with median follow-up of more than 6.3 years, 177Lu-DOTATATE prolonged median OS by 11.7 months versus high-dose octreotide in patients with advanced, progressive, well-differentiated midgut neuroendocrine tumours, although OS difference did not reach statistical significance (HR, 0.84 [95% CI: 0.60, 1.17]; p = 0.30). This analysis used the proportional-hazards...